Abstract—
Cramizol, an imidazole derivative, exhibits lipid-lowering and anti-atherogenic effects. In animals with acute hyperlipidemia induced by Triton WR-1339 cramizol reduced blood levels of cholesterol and triglycerides, and also the atherogenic index. Cramizol and the lipid-lowering drug fenofibrate demonstrated similar effectiveness as hypolipidemic agents. Cramizol also restored the expression of the Apoa1 gene in rats with experimentally induced hyperlipidemia to normal values. This may be a basis of its hypolipidemic and anti-atherogenic action.
Similar content being viewed by others
REFERENCES
Okunevich, I.V., Sapronov, N.S., Khnychenko, L.K., and Shabanov, P.D., Rus. Patent no. 2598347, Byul. Izobret., 2016, no. 26, pp. 1−15.
Gsaller, F., Hortschansky, P., Furukawa, T., Carr, P.D., Rash, B., Capilla, J., Müller, C., Bracher, F., Bowyer, P., Haas, H., Brakhage, A.A., and Bromley, M.J., PLoS Pathogens, 2016, vol. 12, no. 7, e1005775. https://doi.org/10.1371/journal.ppat.1005775
Gupta, A.K., Sexton, R.C., and Rudney, H., J. Lipid Res., 1990, vol. 31, pp. 203−215.
Dautova, G.S., Kosych, V.A., Repin, V.C., and Kamburg, R.A., Eksper. Klin. Farmakol., 1994, vol. 57, no. 5, pp. 21−24.
Barter, P.J. and Rye, K.A., Curr. Opin. Lipidol., 1996, vol. 7, no.2, pp. 82−87.
Mohamad, N., Ananthramaiah, G.M., Reddy, S.T., van Lenten, B.J., Ansell, B.J., Fonarow, G.C., Vahabzadeh, K., Hama, S., Hough, G., Kamranpour, N., Berliner, J.A., Lusis, A.J., and Fogelman, A.M., J. Lipid Res., 2004, vol. 45, pp. 993−1007. https://doi.org/10.1194/jlr.R400001-JLR200
Okunevich, I.V., Khnychenko, L.K., and Shabanov, P.D., Obzory Klin. Farmakol. Lek. Ter., 2014, vol. 12, no. 30, pp. 26−29. https://doi.org/10.17816/RCF12326-29
Khnychenko, L.K., Okunevich, I.V., Losev, N.A., Sapronov, N.S., Patol. Fiziol. Eksper. Ter., 2016, vol. 60, no. 1, pp. 36−39. https://doi.org/10.25557/0031-2991.2016.01.%25p
Abe, C., Ikeda, S., Uchida, T., Yamashita, K., and Ichikawa, T., J. Nutrition Nutrient Physiology,Metabolism, and Nutrient—Nutrient Interactions, 2007, vol. 137, pp. 345−350. https://doi.org/10.1093/jn/137.2.345
Vandesompele, J., De Preter, K., Pattyn, F., Poppe, B., van Roy, N., de Paepe A., and Speleman, F., Genome Biology, 2002, vol. 3, no. 7, pp. 0034.1−0034.11. https://doi.org/10.1186/gb/2002.3.7.research0034
Shavva, V.S., Bogomolova, A.M., Nikitin, A.A., Dizhe, E.B., Tanyanskiy, D.A., Efremov, A.M., Oleinikova, G.N., Perevozchikov, A.P., and Orlov, S.V., J. Cell. Biochem., 2017, vol. 118, pp. 382−396. https://doi.org/10.1002/jcb.25651
Nedoshivin, A.O., Cytoprotectors in the treatment of heart failure in patients with coronary heart disease, Doctorate Dissertation, Saint-Petersburg, Research Institute of Cardiology, 2002.
Tenenbaum, A. and Fisman, E.Z., Cardiovascular Diabetology, 2012, vol. 11, no. 125, pp. 1−10. https://doi.org/10.1186/1475-2840-11-125
Burri, L., Thoresen, G.H., and Berge, R.K., PPAR Research, 2010, vol. 2010, ID 542359, 1−11. https://doi.org/10.1155/2010/542359
ACKNOWLEDGMENTS
The authors are very grateful to Dr N.N. Klyueva, a researcher at the Department of Biochemistry (IEM), for methodological assistance during this work.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
The experiments were performed in accordance with the principles of humanity (EU Directive No. 86/609 of the EU) and approved by the IEM Ethics Committee.
The authors declare that they have no conflict of interest.
Additional information
Translated by A. Medvedev
Rights and permissions
About this article
Cite this article
Lizunov, A.V., Okunevich, I.V., Orlov, S.V. et al. The Effect of Сramizol on ApoA1 Gene Expression in Rats with Experimental Hyperlipidemia. Biochem. Moscow Suppl. Ser. B 14, 82–85 (2020). https://doi.org/10.1134/S1990750820010102
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1134/S1990750820010102